AB Science SA

AB Science - Summary of the presentation on masitinib in ALS delivered at 2023 AAN Annual Meeting

27 Apr 2023 14:41:14 By Nasdaq GlobeNewswire

AB Science announces the success of its capital increase by private placement for an amount of 15 million euros

24 Apr 2023 02:05:09 By Nasdaq GlobeNewswire

AB Science announces the implementation of a new strategy and the launch of a capital increase

21 Apr 2023 16:26:19 By Nasdaq GlobeNewswire

AB Science announces masitinib patent granted in Japan for the treatment of amyotrophic lateral sclerosis, strengthening the Company’s intellectual property position until 2037

18 Apr 2023 12:55:51 By Nasdaq GlobeNewswire

AB Science: Results of masitinib in ALS selected for a scientific platform presentation at the AAN 2023, including long-term survival analysis and a new analysis of patient population with no complete loss of function at baseline

12 Apr 2023 12:23:23 By Nasdaq GlobeNewswire

AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral sclerosis and clarifies the new timeline for responding to Health Canada

04 Apr 2023 12:10:02 By Nasdaq GlobeNewswire

AB Science will host a live webcast on its microtubule destabilizer agents (MDA) platform on Thursday March 16, 2023, from 6pm to 7pm CET

15 Mar 2023 13:05:03 By Nasdaq GlobeNewswire

AB Science announced the publication of the masitinib pivotal phase 3 clinical trial in Alzheimer’s Disease in the journal Alzheimer's Research & Therapy

28 Feb 2023 02:03:43 By Nasdaq GlobeNewswire

AB Science announces the drawdown of the second tranche of 6 million euros under its financing agreement with the European Investment Bank

31 Jan 2023 12:17:01 By Nasdaq GlobeNewswire

AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

29 Dec 2022 12:08:58 By Nasdaq GlobeNewswire

Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

27 Dec 2022 13:04:45 By Nasdaq GlobeNewswire

AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment Bank

22 Dec 2022 12:10:29 By Nasdaq GlobeNewswire

AB Science receives Notice of Deficiency (NOD) from Health Canada for masitinib in the treatment of amyotrophic lateral sclerosis (ALS)

13 Dec 2022 12:08:12 By Nasdaq GlobeNewswire

AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s Disease

21 Nov 2022 12:09:53 By Nasdaq GlobeNewswire

AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s disease

10 Oct 2022 12:04:50 By Nasdaq GlobeNewswire

AB Science today reports its revenues for the first half of 2022 and provides an update on its activities

30 Sep 2022 12:39:50 By Nasdaq GlobeNewswire

AB Science - Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating the antiviral activity of masitinib in Covid-19

14 Sep 2022 12:21:04 By Nasdaq GlobeNewswire

AB Science announces that it has filed an application for conditional Marketing Authorization to EMA for masitinib in the treatment of ALS

24 Aug 2022 13:06:59 By Nasdaq GlobeNewswire

AB Science today announced publication of results from its positive study of masitinib in severe asthma uncontrolled by oral corticosteroids in the peer-reviewed Journal of Asthma and Allergy

07 Jun 2022 11:45:45 By Nasdaq GlobeNewswire

AB Science announces that Health Canada has started the review of New Drug Submission for masitinib in the treatment of ALS

26 May 2022 16:46:10 By Nasdaq GlobeNewswire